LTX-315 is an oncolytic peptide designed to selectively target and disrupt the membranes of cancer cells, particularly within solid tumors. It induces immunogenic cell death by causing rapid lysis of tumor cells, releasing tumor-associated antigens and danger signals that activate the immune system. This promotes a systemic anti-tumor immune response, making it a promising candidate for cancer immunotherapy. It has shown potential in combination with checkpoint inhibitors, enhancing their efficacy by turning immunologically "cold" tumors "hot." LTX-315 is being investigated in clinical trials for cancers such as melanoma, sarcoma, and other advanced solid tumors. Its ability to remodel the tumor microenvironment supports its use in overcoming resistance to existing immunotherapies.